Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 4/20 | 0.48 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.43 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307576 | 0.97 | NRP1 (0.47) | NRP1NMUR2NMUR1GRB2BDKRB2 | |
| SCHEMBL30716924 | 0.96 | NRP1 (0.45) | NRP1NMUR2NMUR1GRB2F2 | |
| SCHEMBL31399622 | 0.94 | NRP1 (0.49) | NRP1NMUR2NMUR1F2 | |
| SCHEMBL30855542 | 0.94 | NRP1 (0.49) | NRP1NMUR2NMUR1F2 | |
| SCHEMBL31034440 | 0.94 | NRP1 (0.44) | NRP1NMUR2NMUR1GRB2EPHA2 | |
| SCHEMBL30997452 | 0.92 | NRP1 (0.43) | NRP1NMUR2NMUR1GRB2F2 | |
| SCHEMBL29591906 | 0.91 | GRB2 (0.46) | NRP1NMUR2NMUR1GRB2BDKRB2 | |
| SCHEMBL29872595 | 0.91 | NRP1 (0.54) | NRP1F2 | |
| SCHEMBL7949048 | 0.91 | F2 (0.48) | NRP1F2 | |
| SCHEMBL1163558 | 0.90 | F2 (0.44) | NRP1NMUR2NMUR1GRB2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611440-B2 | Fusion proteins and uses thereof | SYNKLINO A/S (DK) | 2026-04-28 | — | — | US | disclosed |
| CN-114341196-B | Fusion proteins and uses thereof | 辛克利诺公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240147984-A1 | COMPOSITIONS FOR EX VIVO ORGAN CARE | SYNKLINO A/S (DK) | 2024-05-09 | — | — | US | disclosed |
| US-20220288160-A1 | FUSION PROTEINS AND USES THEREOF | SYNKLINO A/S (DK) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611440-B2 | Fusion proteins and uses thereof | TIMCC, CX3CR1, CXCL10 | NRP1 719/4885NMUR2 1771/4885NMUR1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.